Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea

PHASE3CompletedINTERVENTIONAL
Enrollment

16,000

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Yaws
Interventions
DRUG

Azithromycin

"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"

Trial Locations (1)

034

Lihir Medical Centre, Londolovit

Sponsors
All Listed Sponsors
collaborator

Barcelona Institute for Global Health

OTHER

collaborator

National Department of Health of Papua New Guinea

UNKNOWN

collaborator

World Health Organization

OTHER

collaborator

University of Washington

OTHER

lead

Lihir Medical Centre

OTHER

NCT01955252 - Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea | Biotech Hunter | Biotech Hunter